Literature DB >> 16904447

Inverted papilloma of urinary bladder: is long-term cystoscopic surveillance needed? A single center's experience.

Henry Ho1, Y D Chen, P H Tan, M Wang, W K O Lau, Christopher Cheng.   

Abstract

OBJECTIVES: To review all cases of urinary bladder inverted papilloma (IP) in our institution and determine the need for cystoscopic surveillance. IP is an uncommon benign tumor of the urinary tract. Its multiplicity, recurrence, and association with transitional cell carcinoma (TCC) suggest possible malignant potential, leading to conflicting clinical conclusions regarding the need for surveillance.
METHODS: All consecutive patients from January 1991 to December 2004 with IP were included in this study. A single pathologist performed the histologic review. The patients had undergone cystoscopy and ultrasound evaluation of the kidneys every 6 months.
RESULTS: Of the 52 patients, 45 were men and 7 were women. The average age at presentation was 58.9 +/- 11.8 years (range 30 to 79). No patient had a synchronous or previous bladder tumor. The most common complaint was macroscopic hematuria. Ten cases were incidental findings during bladder ultrasonography or cystoscopy. All were solitary tumors, most commonly found at the bladder neck. The average follow-up period was 62 +/- 23 months, with no recurrence. One case of subsequent noninvasive papillary TCC developed 15 months later. The initial histologic findings had revealed cytologic atypia, with suspicious urine cytology findings. On review, it was more compatible with TCC with an inverted pattern.
CONCLUSIONS: Although our cases exhibited benign biologic behavior, the presence of cytologic atypia and suspicious urine cytology require exclusion of TCC with an inverted pattern. Thus, in histologically proven solitary bladder IP with no associated TCC, cystoscopic surveillance may not be necessary.

Entities:  

Mesh:

Year:  2006        PMID: 16904447     DOI: 10.1016/j.urology.2006.03.014

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  7 in total

Review 1.  Inverted urothelial papilloma: A review of diagnostic pitfalls and clinical management.

Authors:  Mary K Sweeney; Soroush Rais-Bahrami; Jennifer Gordetsky
Journal:  Can Urol Assoc J       Date:  2017 Jan-Feb       Impact factor: 1.862

2.  Inverted papilloma of the ureter: study of a rare case with emphasis on clinicopathologic implications.

Authors:  Nikolaos Mertziotis; Diomidis Kozyrakis; Andreas Petrolekas; Maria Terzi; Nikiforos Kapranos
Journal:  Can Urol Assoc J       Date:  2012-12       Impact factor: 1.862

Review 3.  The pathology of urinary bladder lesions with an inverted growth pattern.

Authors:  Aitao Guo; Aijun Liu; Xiaodong Teng
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

4.  Immunohistochemistry and Fluorescence In Situ Hybridization Can Inform the Differential Diagnosis of Low-Grade Noninvasive Urothelial Carcinoma with an Inverted Growth Pattern and Inverted Urothelial Papilloma.

Authors:  Juan-Juan Sun; Yong Wu; Yong-Ming Lu; Hui-Zhi Zhang; Tao Wang; Xiao-Qun Yang; Meng-Hong Sun; Chao-Fu Wang
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

5.  [Inverted papilloma of the bladder: a rare benign tumor: a case report].

Authors:  Hicham El Bote; Sihem Atik; Rami Fares; Ernest Hage
Journal:  Pan Afr Med J       Date:  2017-04-13

6.  Proteomic-Based Machine Learning Analysis Reveals PYGB as a Novel Immunohistochemical Biomarker to Distinguish Inverted Urothelial Papilloma From Low-Grade Papillary Urothelial Carcinoma With Inverted Growth.

Authors:  Minsun Jung; Cheol Lee; Dohyun Han; Kwangsoo Kim; Sunah Yang; Ilias P Nikas; Kyung Chul Moon; Hyeyoon Kim; Min Ji Song; Bohyun Kim; Hyebin Lee; Han Suk Ryu
Journal:  Front Oncol       Date:  2022-03-24       Impact factor: 6.244

7.  HRAS mutations are frequent in inverted urothelial neoplasms.

Authors:  Andrew S McDaniel; Yali Zhai; Kathleen R Cho; Saravana M Dhanasekaran; Jeffrey S Montgomery; Ganesh Palapattu; Javed Siddiqui; Todd Morgan; Ajjai Alva; Alon Weizer; Cheryl T Lee; Arul M Chinnaiyan; Michael J Quist; Catherine S Grasso; Scott A Tomlins; Rohit Mehra
Journal:  Hum Pathol       Date:  2014-06-18       Impact factor: 3.466

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.